Here is what you need to read before #ECTRIMS2015
1. Could Genentech’s Ocrelizumab Become the First Effective Primary Progressive MS Therapy?
2. Ocrelizumab: a Promising New Treatment for Multiple Sclerosis with Minimal Side Effects
4. Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA
5. EMD Serono To Present New Data on Rebif, a Therapy for RRMS, at Upcoming ECTRIMS Congress
6. Receptos Launches SUNBEAM Phase 3 Trial for Relapsing Multiple Sclerosis Therapy
8. Most MS Survey Respondents Favor Legal Marijuana Access For Medical Use
9. Stem Cells Used to Treat Secondary Progressive Patients in Clinical Trial
10. Study Supports High Intensity Exercise to Improve Muscle Condition in MS Patients